top of page

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

  • Sep 12, 2024
  • 1 min read

CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target. This new fundraising brings total series B funds raised to £43.25 million.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page